Delcath Systems (NASDAQ:DCTH) Delivers Shareholders Incredible 358% Return Over 1 Year, Surging 20% in the Last Week Alone

Simply Wall StDec 3 08:01 ET

CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsDec 3 07:31 ET · Ratings

Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer

BenzingaDec 2 08:36 ET

Express News | Delcath Systems Inc - Primary Endpoint Data Expected by End of 2027

ReutersDec 2 08:31 ET

Express News | Delcath Systems Announces FDA Clearance of Ind Application for Phase 2 Clinical Trial of Hepzato™ in Liver-Dominant Metastatic Colorectal Cancer

ReutersDec 2 08:30 ET

H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 11 06:31 ET · Ratings